Emerging ResearchLegal to Compound
AOD-9604 Dosing Guide
Evidence-based dosing protocols across 1 administration approach.
Medical Disclaimer
This dosing information is for educational reference only. Dosing decisions require physician oversight. Do not self-prescribe or adjust dosing without consulting a qualified healthcare provider.
Dosing Protocols
Phase IIb Trial (Oral)
Clinical TrialOralDose Range
1–1 mg
Frequency
daily
Source
PMC3584306; Metabolic Pharmaceuticals Ltd.
Development TERMINATED 2007. Failed primary endpoint in largest Phase IIb. Never advanced to Phase III. 1 mg/d → 2.6 kg weight loss vs 0.8 kg placebo (12 wk).
Administration
Delivery methods
Subcutaneous injection
⏳
Pending physician review — consult your provider before use.Updated 2026-04-10